Giant Biogene offers discounted, net-cash-backed exposure to recombinant collagen, with medical-aesthetics launches providing upside if channel restructuring and margin recovery succeed.
Overview
Giant Biogene is a vertically integrated synthetic-biology company focused on recombinant collagen and rare ginsenosides, commercialized through functional skincare, medical dressings, Class III aesthetic devices, and functional foods. Comfy and Collgene anchor its consumer portfolio, while hospitals, clinics, pharmacies, and DTC platforms provide complementary distribution; direct sales represented approximately 76.6% of revenue. The company’s moat rests on 186 patents, high-purity human-homologous proteins, clinical data, professional trust, and NMPA registrations that can require three to five years to secure. Near-term financial performance is weak: H1 2026 revenue fell 6.3% to RMB 2,917.69 million, gross margin declined 220 basis points to 79.5%, selling expenses rose 19.7% to RMB 1,266.80 million, and attributable net profit dropped 20.5% to RMB 939.71 million. **The transition is costly, but the balance sheet is exceptionally strong**, with RMB 8.29 billion of cash and short-term investments and minimal debt. At HKD 28.44, the stock trades at 12.7x–14.1x trailing P/E, below historic levels. **The principal catalyst is clinical adoption of the 753 Collagen Needle and neck-wrinkle filler**, which could offset slower skincare growth and support re-rating.